Literature DB >> 24861870

Tumor markers are more useful in patients undergoing surveillance for hepatocellular carcinoma with unreliable results by ultrasonography.

Shintaro Mikami1, Ryosuke Tateishi, Shu Hagiwara, Masaya Sato, Tatsuya Minami, Koji Uchino, Kenichiro Enooku, Takahisa Sato, Hayato Nakagawa, Ryota Masuzaki, Yoshinari Asaoka, Yuji Kondo, Shuichiro Shiina, Hitoshi Ikeda, Masao Omata, Haruhiko Yoshida, Kazuhiko Koike.   

Abstract

AIM: The objectives of this study was to evaluate the utility of tumor markers in hepatocellular carcinoma (HCC) surveillance based on the reliability of ultrasonography.
METHODS: We analyzed 313 patients with HCC detected through a surveillance program using ultrasonography combined with three tumor markers from February 2000 to December 2010. The patients were categorized into two groups based on the triggering event: the US group (n = 281) in which a tumor was first detected using ultrasonography and the TM group (n = 32) in which elevated tumor markers led to the diagnosis of a tumor that was undetected using ultrasonography. The reliability of ultrasonography was scored on a 4-point scale based on three items (coarseness of liver parenchyma, patient obesity and liver atrophy). Additionally, patient survival was assessed using the Kaplan-Meier method and log-rank test.
RESULTS: The median tumor size was 20 mm (interquartile range, 15-24). The reliability of ultrasonography was evaluated as good in 208 (66.5%), satisfactory in 80 (8.0%), poor in 21 (6.7%) and unsatisfactory in four (1.2%) patients. The proportion of patients in the TM group increased significantly according to the score, from 7.2% to 25.0% (P = 0.01). The survival rates of patients at 3 and 5 years were 83.7% and 57.2% in the US group, and 79.3% and 59.4% in the TM group, respectively (P = 0.98).
CONCLUSION: Tumor markers may play a diagnostic role in patients with unreliable ultrasonography results. The survival of patients diagnosed by elevated tumor markers was not significantly different from those diagnosed by ultrasonography.
© 2014 The Japan Society of Hepatology.

Entities:  

Keywords:  hepatocellular carcinoma; surveillance; tumor marker; ultrasonography

Year:  2014        PMID: 24861870     DOI: 10.1111/hepr.12365

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  4 in total

1.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Authors:  Mohammed Eslam; Shiv K Sarin; Vincent Wai-Sun Wong; Jian-Gao Fan; Takumi Kawaguchi; Sang Hoon Ahn; Ming-Hua Zheng; Gamal Shiha; Yusuf Yilmaz; Rino Gani; Shahinul Alam; Yock Young Dan; Jia-Horng Kao; Saeed Hamid; Ian Homer Cua; Wah-Kheong Chan; Diana Payawal; Soek-Siam Tan; Tawesak Tanwandee; Leon A Adams; Manoj Kumar; Masao Omata; Jacob George
Journal:  Hepatol Int       Date:  2020-10-01       Impact factor: 6.047

2.  Serum monomeric laminin-γ2 as a novel biomarker for hepatocellular carcinoma.

Authors:  Hirofumi Kiyokawa; Hiroshi Yasuda; Ritsuko Oikawa; Chiaki Okuse; Nobuyuki Matsumoto; Hiroki Ikeda; Tsunamasa Watanabe; Hiroyuki Yamamoto; Fumio Itoh; Takehito Otsubo; Toru Yoshimura; Eisaku Yoshida; Masatoshi Nakagawa; Naohiko Koshikawa; Motoharu Seiki
Journal:  Cancer Sci       Date:  2017-06-02       Impact factor: 6.716

3.  Sensitivity of ultrasound in detecting hepatocellular carcinoma in obese patients compared to explant pathology as the gold standard.

Authors:  Jamak Modaresi Esfeh; Kaveh Hajifathalian; Kianoush Ansari-Gilani
Journal:  Clin Mol Hepatol       Date:  2019-11-15

4.  The egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Authors:  Yasser Fouad; Gamal Esmat; Reda Elwakil; Serag Zakaria; Ayman Yosry; Imam Waked; Maissa El-Razky; Wahid Doss; Magdy El-Serafy; Ebraheem Mostafa; Mahmood Anees; Mohamed A Sakr; Nadia AbdelAty; Ashraf Omar; Samy Zaki; Amgad Al-Zahaby; Hamdy Mahfouz; Maysaa Abdalla; Mahmoud Albendary; Abdel-Khalek Hamed; Ahmed Gomaa; Adel Hasan; Sherif Abdel-Baky; Medhat El Sahhar; Gamal Shiha; Dina Attia; Ebada Saeed; Enas Kamal; Shamardan Bazeed; Mai Mehrez; Shereen Abdelaleem; Yasmine Gaber; Mohammed Abdallah; Asmaa Salama; Doaa A Tawab; Shaymaa Nafady
Journal:  Saudi J Gastroenterol       Date:  2022 Jan-Feb       Impact factor: 2.485

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.